Recently, APhA issued a press release and social media regarding a congressional win for the profession that allows pharmacists to be recognized by DEA—if permitted by their state—as prescribers for buprenorphine.
Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, Executive vice president and CEO of APhA